Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter
continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving
CPX-351 as their usual medical care administered according to FDA approval, as a condition
for participation.